Diabetic vascular diseases: molecular mechanisms and therapeutic strategies

Y Li, Y Liu, S Liu, M Gao, W Wang, K Chen… - Signal transduction and …, 2023 - nature.com
Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

Emerging therapies for Charcot-Marie-Tooth inherited neuropathies

M Stavrou, I Sargiannidou, E Georgiou… - International Journal of …, 2021 - mdpi.com
Inherited neuropathies known as Charcot-Marie-Tooth (CMT) disease are genetically
heterogeneous disorders affecting the peripheral nerves, causing significant and slowly …

100,000 genomes pilot on rare-disease diagnosis in health care—preliminary report

100,000 Genomes Project Pilot … - New England Journal of …, 2021 - Mass Medical Soc
Abstract Background The UK 100,000 Genomes Project is in the process of investigating the
role of genome sequencing in patients with undiagnosed rare diseases after usual care and …

Deep structured learning for variant prioritization in Mendelian diseases

MC Danzi, MF Dohrn, S Fazal, D Beijer… - Nature …, 2023 - nature.com
Effective computer-aided or automated variant evaluations for monogenic diseases will
expedite clinical diagnostic and research efforts of known and novel disease-causing genes …

Challenges in treating Charcot-Marie-Tooth disease and related neuropathies: current management and future perspectives

C Pisciotta, P Saveri, D Pareyson - Brain sciences, 2021 - mdpi.com
There is still no effective drug treatment available for Charcot-Marie-Tooth neuropathies
(CMT). Current management relies on rehabilitation therapy, surgery for skeletal deformities …

Recent advances in the treatment of Charcot‐Marie‐Tooth neuropathies

A Bolino, M D'Antonio - Journal of the Peripheral Nervous …, 2023 - Wiley Online Library
Abstract Charcot‐Marie‐Tooth (CMT) neuropathies are one of the most common
neuromuscular disorders. However, despite the identification of more than 100 causative …

Sorbitol is a severity biomarker for PMM2‐CDG with therapeutic implications

AN Ligezka, S Radenkovic, M Saraswat… - Annals of …, 2021 - Wiley Online Library
Objective Epalrestat, an aldose reductase inhibitor increases phosphomannomutase (PMM)
enzyme activity in a PMM2‐congenital disorders of glycosylation (CDG) worm model …

Distal hereditary motor neuropathies: mutation spectrum and genotype–phenotype correlation

M Frasquet, R Rojas‐García… - European journal of …, 2021 - Wiley Online Library
Background and purpose Distal hereditary motor neuropathies (dHMNs) are a
heterogeneous group of disorders characterized by degeneration of the motor component of …

Trials for slowly progressive neurogenetic diseases need surrogate endpoints

MM Reilly, DN Herrmann, D Pareyson… - Annals of …, 2023 - Wiley Online Library
Heritable neurological disorders provide insights into disease mechanisms that permit
development of novel therapeutic approaches including antisense oligonucleotides, RNA …

Long-term consumption of the sugar substitute sorbitol alters gut microbiome and induces glucose intolerance in mice

CH Li, CT Wang, YJ Lin, HY Kuo, JS Wu, TC Hong… - Life Sciences, 2022 - Elsevier
Aims Epidemic obesity and diabetes have led to increased use of low-calorie sweeteners.
Although several studies have suggested that consumption of artificial sweeteners, such as …